First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800.

ABSTRACT:

Introduction

Maximizing extent of surgical resection with the least morbidity remains critical for survival in glioblastoma patients, and we hypothesize that it can be improved by enhancements in intraoperative tumor detection. In a clinical study, we determined if therapeutic antibodies could be repurposed for intraoperative imaging during resection.

Methods

Fluorescently labeled cetuximab-IRDye800 was systemically administered to three patients 2 days prior to surgery. Near-infrared fluorescence imaging of tumor and histologically negative peri-tumoral tissue was performed intraoperatively and ex vivo. Fluorescence was measured as mean fluorescence intensity (MFI), and tumor-to-background ratios (TBRs) were calculated by comparing MFIs of tumor and histologically uninvolve

SUBMITTER: Miller SE 

PROVIDER: S-EPMC6031450 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature